{'fraction_non_alphanumeric': 0.023391812865497075, 'fraction_numerical': 0.014944769330734242, 'mean_word_length': 4.9689922480620154, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Phase 3 trials suggest ways to improve current hematologic cancer therapies.

be determined. That may change by early in the next decade, when results are expected from 3 large trials of combination therapies. Brown is leading the Niacin Plus Statin to Prevent Vascular Events (AIM HIGH) trial, randomizing 6600 patients with established vascular disease and atherogenic dyslipidemia to either simvastatin or an extendedrelease combination therapy of niacin and simvastatin. These patients will be followed up for a median of 4 years to see if the combination therapy delays the time to a first major cardiovascular disease event. Another trial is the HPS2-THRIVE (Treatment of HDL to Reduce the Incidence of Vascular Events) study of 20 000 patients in the United Kingdom, China, and Scandinavia to determine if combining niacin with a new drug (MK-0524A) that minimizes flushing can reduce cardiovascular disease risk in patients already effectively treating their low-density lipoprotein cholesterol (LDL-C) levels. The study is sponsored by Merck & Co Inc (Whitehouse Station, NJ). The third study is an arm of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. A portion of the 10 251 study participants with type 2 diabetes mellitus are being followed up to determine if, in the context of good glycemic control, raising HDL-C and lowering triglyceride and LDL-C levels with a combination of a fibrate and a statin reduces the rate of cardiovascular events compared with statin therapy only for treatment of LDL-C.